EXPERT VIEW: Patent attorney Gareth Williams speaks about the potential issues facing the pharmaceutical industry

18 July 2013

As patent expiration becomes an increasing hurdle for pharma companies worldwide, The Pharma Letter spoke to patent attorney Gareth Williams, a partner at Marks & Clerk solicitors in Cambridge, UK, about why patents in other sectors outnumber those in pharma and biotech, why you can’t patent DNA in the USA and how the future of patents in Europe will be interesting.

The Pharma Letter: Are patent applications in the pharma and biotech sectors increasing or decreasing?

Gareth Williams: The latest filing figures from the European Patent Office (EPO) show a slight drop in pharma and biotech European patent filings in 2012 when compared with 2011 figures – down 0.2% and 4.3% respectively – continuing a downward trend from 2010. However, international applications (according to statistics produced by the World Intellectual Property Organization or WIPO) show a very slight increase in these fields over the same period. So it’s probably fair on balance to say that filings are generally flat, rather than any clear upward or downward trend.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK